SlideShare a Scribd company logo
1 of 41
3‫شعبان‬1436
Two ideas of ovarian stimulation
N.B: The main endogenous
hormone modulates
endogenous gonadotropins
secretion is Estrogen
3‫شعبان‬1436AHMAD SABER
As estrogen is the main hormone in
regulating production of endogenous
gonadotropins
SO IT IS A TARGET HORMONE
Estrogen Receptor Modulator
SERM
Clomphine
Citerate
Tamoxifen
Aromatase Enzyme inhibition
Letrozole
3‫شعبان‬1436AHMAD SABER
Clomiphene citerate
3‫شعبان‬1436AHMAD SABER
3‫شعبان‬1436AHMAD SABER
Non-steroidal triphenylethylene derivative
Cis / Trans isomerism ( same number of atoms but
different orientation
Chemical structure & Pharmacokinetics:
3‫شعبان‬1436AHMAD SABER
EnclomipheneZuclomiphene
More potent antiestrogenic isomerLess potent antiestrogenic action
(good?)
The main role in ovarian
stimulation
Minimal role in ovarian stimulation
½ life few daysDetected in the circulation for
about one month after last day of
administration
62% of clomiphene moleculeOnly 38% of clomiphene molecule
Hepatic elimination: avoided in cases of liver impairment
Retained in body fat so variable in half life and elimination
& dose must be adjusted according to BMI
Clomid used Cycle –ON
/Cycle-off
3‫شعبان‬1436
Early optimal start may antiestrogenic
effect
Strong anti estrogen
+
Weak estrogenic activity
Competitive antagonist=
3‫شعبان‬1436AHMAD SABER
WhereCCacts?
Outside CNS
antiestrogenic effect
of CC is Hostile
3‫شعبان‬1436AHMAD SABER
3‫شعبان‬1436AHMAD SABER
Due to its site of action, the total daily
dose of clomiphene must be taken at
one time to optimize entry into the
hypothalamic and central nervous
system receptor sites
3‫شعبان‬1436AHMAD SABER
Hostile actions of CC is due to
antagonism of E receptors in
the uterus
Poor cervical mucus quality
or quantity and fewer than
five motile sperm was found
in 39 of 100 patients
referred for gonadotropin
ovulation induction and/or
IUI because of failure to
become pregnant after 3- 8
clomiphene cycles (Dickey
2006).
Reduced endometrial
thickness
See later
What antiestrogenic
effect forces you to
stop CC
immediately?
3‫شعبان‬1436AHMAD SABER
3‫شعبان‬1436AHMAD SABER
Scotoma
Initial evaluation & prerequisites before
induction
TVS scanning
Hormonal
profile
Critical US values for
ovulation induction
Endometrial changes during ovulation
induction
• When clomiphene citrate (CC) is used for ovulation induction,
endometrial thickness is often decreased compared with
spontaneous cycles during and immediately following the days
CC is taken, because of its antiestrogen effect
• During the late proliferative phase, endometrial thickness
increases at a faster rate in CC cycles than in spontaneous
cycles as it escapes from the antiestrogen, and the effect of
increased estrogen due to multiple follicle growth becomes
manifest.
3‫شعبان‬1436AHMAD SABER
Double endometrial thickness (mm) in spontaneous (○) and clomiphene citrate (●)
cycles (mean + SEM). LH 0 = day of onset of luteinizing hormone surge. *P < 0.05. From
Randall and Templeton (1991) [7].
Reproduced with permission of the authors and the publisher, the American Society
for Reproductive Medicine (The American Fertility Society).
3‫شعبان‬1436AHMAD SABER
How to measure the endometrial thickness
Thickness measured in an anterior–posterior view at the widest point from outside to
outside in an anterior-posterior view at the widest point (O–O).
The pattern is triple-line. 3‫شعبان‬1436
3‫شعبان‬1436AHMAD SABER
1. Endometrial pattern
• A triple-line pattern on the day of hCG administration has been
reported by some authors to be necessary for implantation in
controlled ovarian hyperstimulation (COH) cycles, where hMG or
FSH is administered,.
• However, Dickey et al. found no difference in initial pregnancy
rate between a triple-line pattern (10.9%) and intermediate
pattern (10.2%) in CC and COH cycles for ovulation induction
before intrauterine insemination, but noted a difference in
continuing pregnancy rates of 9.4% for the triple-line pattern
and 7.3% for the intermediate pattern .
3‫شعبان‬1436AHMAD SABER
2. Endometrial thickness
Decreased endometrial thickness is linked to failure to conceive and
biochemical pregnancy in CC, hMG, and spontaneous
cycles[13,14,15].
In a study of endometrial thickness on the day of hCG administration
for timed intrauterine insemination (IUI), optimal pregnancy and birth
(continuing pregnancy) rates occurred only when endometrial
thickness was 9mm or greater on the day of hCG administration
(Table 12.1).
More importantly, no pregnancies occurred when endometrial
thickness was less than 6mm in spontaneous, CC, or hMG IUI cycles
[13,14].
3‫شعبان‬1436AHMAD SABER
Endometrial thickness according to ovulation regimen:
percent cycles; figures in parentheses are number of cycles
Endometrial thickness vs. outcome in ovulation induction
intrauterine insemination cycles
Ovarian cyst before ovulation induction
• Ovarian cysts larger than 4 cm should be assessed
by M-B rules according to IOTA trial 2010.
• Smaller cysts without cancer characteristics either
followed until they resolve or start your induction
agent.
• COCs has no role in treatment ovarian cyst but
may have a role in prevention other cysts
formation.
3‫شعبان‬1436AHMAD SABER
Dealing with problems
detected by US
3‫شعبان‬1436AHMAD SABER
Ovarian
cyst
Thick
endometrium
Hormonal profile
3‫شعبان‬1436AHMAD SABER
Baseline Estradiol
CC will be ineffective if E ˂ 45-60 pg/ml ( Disturbed axis)
prolactin˃25 mIu/ml
Indicates ttt of hyperprolactinemia
DHEAS if ˃180 μg/dl indicates adrenal hyperplasia
Fasting insulin
In cases of insulinresistance associated with PCOs
TSH levels 4.5 mIU/mL or
higher are diagnostic of subclinicalhypothyroidism.
Insulin resistance in PCO cases
• Fasting insulin levels greater than 20 lU/mL
• Two-hour glucose/insulin response to a 75 g glucose load
 Two-hour insulin level of 100–150 lU/mL indicates
probable IR, 150–300 lU/mL is diagnostic for IR, and
greater than 300 lU/mL indicates severe IR.
 Two-hour glucose of 140–199 mg/dL indicates impaired
glucose tolerance; 200 mg/dL indicates noninsulin-
dependent diabetes (type II diabetes).
3‫شعبان‬1436
To summarize, the initial Prerequisites
Regular
menses
TSH
Day 21 P
Androgen
excess
DHEAS/17OH P
Glucose/Insulin
FSH/LH/E
Amenorrhea
FSH/E
PRL
hCG
Irregular
menses
TSH
FSH/LH/E
Glucose/insulin
Serum FSH ˂ 25 mIu/ml
Endometrial thickness ˂ 6 mm
No ovarian cyst ˃ 3 cm
serum E levels ˃ menopausal (20 pg/mL)
Teratogenic ( Group X)
Extended action 8-21 days
( stored in body fat cells, depend on isomer)
3‫شعبان‬1436AHMAD SABER
Administration
• Starting Day:
☑ 2nd -7th day for 5 days
 Not effective if started too early i.e.: serum E ˂45-60 pg/ml
 Starting day is affected by length of menstrual cycle ???
 Better results of CC induction are obtained with early optimal start as early start result in
early disappearance of hostile antiestrogenic effect before luteal phase
• Starting Dose:
☑ Depends on BMI (How??) or P level
Luteal phase insufficiency
needs higher starting dose
Follicle
6mm or
greater
3‫شعبان‬1436AHMAD SABER
3‫شعبان‬1436AHMAD SABER
Relationship of Clomiphene Dose to Weight at Conception
Simply, Starting dose in relation to
body wt is:
3‫شعبان‬1436AHMAD SABER
TamoxifenClomipheneWeight
20 mg25 mg
40 mg50 mg
60 mg100 mg
Monitoring of CC induction cycles
3‫شعبان‬1436AHMAD SABER
Follicular monitoring
3‫شعبان‬1436
AHMAD SABER
Increase in diameter at a rate of 1mm per day until they
reach 10 mm, then at a rate of 2mm per day until
ovulation (Steinkampf,2008)
The highest pregnancy rates occur when there are four
follicles 15 mm or larger. When HCG is used to trigger
ovulation, highest pregnancy rates are achieved when
the lead follicle is 16 mm.
All follicles 12 mm or larger (vs. >10mmin
gonadotropin cycles) may ovulate and contribute to a
multiple pregnancy (Dickey et al., 2001).
Endometrial thickness monitoring
Preovulatory thickness should be ˃6 mm and better
pregnancy rate was found with endometrial
thickness 9 mm
3‫شعبان‬1436AHMAD SABER
If 5 days post induction…there is thin endometrium:
Postpone hCG administration
Use Estrogen 4 times/day????
In subsequent cycles use low dose CC or switch to
Tamoxifen
Postovulatory Progesterone
• measured five to seven days after ovulation, to
coincide with the day of embryo implantation.
• supplementation should be considered in the
current cycle and the dose of clomiphene should be
increased as 50-mg increments until progesterone
levels are 2,000 ng/dL (20 pg/mL) or higher in
subsequent cycles.
Value:
confirmovulation
determine if the dose of clomiphene is sufficient.
Methods to Increase Pregnancy Rates in
Clomiphene Cycles
3‫شعبان‬1436AHMAD SABER
1.Increase number of follicles
2.Improve endometrial and
cervical mucous quality
3.IUI
3‫شعبان‬1436AHMAD SABER
Iniections SequentialOral
Thanks
3‫شعبان‬1436AHMAD SABER

More Related Content

What's hot

Therapeutic uses of Progestagen in infertility and IVF
Therapeutic uses of  Progestagen  in infertility and IVF Therapeutic uses of  Progestagen  in infertility and IVF
Therapeutic uses of Progestagen in infertility and IVF Aboubakr Elnashar
 
Ovarian Stimulation Protocols
Ovarian Stimulation ProtocolsOvarian Stimulation Protocols
Ovarian Stimulation ProtocolsHesham Gaber
 
MANAGEMENT OF POOR RESPONDERS IN IVF BY DR SHASHWAT JANI
MANAGEMENT OF POOR RESPONDERS  IN IVF BY DR SHASHWAT JANIMANAGEMENT OF POOR RESPONDERS  IN IVF BY DR SHASHWAT JANI
MANAGEMENT OF POOR RESPONDERS IN IVF BY DR SHASHWAT JANIDR SHASHWAT JANI
 
Controlled Ovarian Hyperstimulation With IUI
Controlled Ovarian Hyperstimulation With IUIControlled Ovarian Hyperstimulation With IUI
Controlled Ovarian Hyperstimulation With IUIBharati Dhorepatil
 
Fertility preservation 3
Fertility preservation 3Fertility preservation 3
Fertility preservation 3Basalama Ali
 
Endometriosis and Infertility
Endometriosis and InfertilityEndometriosis and Infertility
Endometriosis and InfertilityMarwan Alhalabi
 
PREMATURE OVARIAN INSUFFICIENCY ESHRE Guidelines, 2015
PREMATURE OVARIAN INSUFFICIENCY ESHRE Guidelines, 2015PREMATURE OVARIAN INSUFFICIENCY ESHRE Guidelines, 2015
PREMATURE OVARIAN INSUFFICIENCY ESHRE Guidelines, 2015Aboubakr Elnashar
 
Recent advances in stimulation protocols
Recent advances in stimulation protocolsRecent advances in stimulation protocols
Recent advances in stimulation protocolsSandro Esteves
 
Management of poor ovarian reserve- Dr Parul Katiyar
Management of poor ovarian reserve- Dr Parul KatiyarManagement of poor ovarian reserve- Dr Parul Katiyar
Management of poor ovarian reserve- Dr Parul KatiyarDr Parul Katiyar
 
Adjuvants in por (1)
Adjuvants in por (1)Adjuvants in por (1)
Adjuvants in por (1)rupalibassi
 
Ovulation Stimulation Protocols for IUI
Ovulation Stimulation Protocols for IUIOvulation Stimulation Protocols for IUI
Ovulation Stimulation Protocols for IUIBharati Dhorepatil
 
Recurrent implantation failure
Recurrent implantation failureRecurrent implantation failure
Recurrent implantation failureAboubakr Elnashar
 
Endometriosis associated infertility: ESHRE2022
Endometriosis associated infertility: ESHRE2022Endometriosis associated infertility: ESHRE2022
Endometriosis associated infertility: ESHRE2022Aboubakr Elnashar
 
Ovulation induction
Ovulation inductionOvulation induction
Ovulation inductionsunitafeme
 
Thin Endometrium & Infertility
Thin Endometrium & InfertilityThin Endometrium & Infertility
Thin Endometrium & InfertilityLifecare Centre
 
PCOS - Ovulation Induction 2 - Dr Bharati Dhorepatil
PCOS - Ovulation Induction 2 - Dr Bharati DhorepatilPCOS - Ovulation Induction 2 - Dr Bharati Dhorepatil
PCOS - Ovulation Induction 2 - Dr Bharati DhorepatilBharati Dhorepatil
 

What's hot (20)

Therapeutic uses of Progestagen in infertility and IVF
Therapeutic uses of  Progestagen  in infertility and IVF Therapeutic uses of  Progestagen  in infertility and IVF
Therapeutic uses of Progestagen in infertility and IVF
 
Ovarian Stimulation Protocols
Ovarian Stimulation ProtocolsOvarian Stimulation Protocols
Ovarian Stimulation Protocols
 
GnRH antagonists
GnRH antagonistsGnRH antagonists
GnRH antagonists
 
MANAGEMENT OF POOR RESPONDERS IN IVF BY DR SHASHWAT JANI
MANAGEMENT OF POOR RESPONDERS  IN IVF BY DR SHASHWAT JANIMANAGEMENT OF POOR RESPONDERS  IN IVF BY DR SHASHWAT JANI
MANAGEMENT OF POOR RESPONDERS IN IVF BY DR SHASHWAT JANI
 
Controlled Ovarian Hyperstimulation With IUI
Controlled Ovarian Hyperstimulation With IUIControlled Ovarian Hyperstimulation With IUI
Controlled Ovarian Hyperstimulation With IUI
 
Fertility preservation 3
Fertility preservation 3Fertility preservation 3
Fertility preservation 3
 
Endometriosis and Infertility
Endometriosis and InfertilityEndometriosis and Infertility
Endometriosis and Infertility
 
PREMATURE OVARIAN INSUFFICIENCY ESHRE Guidelines, 2015
PREMATURE OVARIAN INSUFFICIENCY ESHRE Guidelines, 2015PREMATURE OVARIAN INSUFFICIENCY ESHRE Guidelines, 2015
PREMATURE OVARIAN INSUFFICIENCY ESHRE Guidelines, 2015
 
Recent advances in stimulation protocols
Recent advances in stimulation protocolsRecent advances in stimulation protocols
Recent advances in stimulation protocols
 
Management of poor ovarian reserve- Dr Parul Katiyar
Management of poor ovarian reserve- Dr Parul KatiyarManagement of poor ovarian reserve- Dr Parul Katiyar
Management of poor ovarian reserve- Dr Parul Katiyar
 
Treatment of decreased ovarian reserve
Treatment of decreased ovarian reserveTreatment of decreased ovarian reserve
Treatment of decreased ovarian reserve
 
Iui - newer concepts
Iui  - newer conceptsIui  - newer concepts
Iui - newer concepts
 
Adjuvants in por (1)
Adjuvants in por (1)Adjuvants in por (1)
Adjuvants in por (1)
 
Ovulation Stimulation Protocols for IUI
Ovulation Stimulation Protocols for IUIOvulation Stimulation Protocols for IUI
Ovulation Stimulation Protocols for IUI
 
Adolescent PCOS
Adolescent PCOSAdolescent PCOS
Adolescent PCOS
 
Recurrent implantation failure
Recurrent implantation failureRecurrent implantation failure
Recurrent implantation failure
 
Endometriosis associated infertility: ESHRE2022
Endometriosis associated infertility: ESHRE2022Endometriosis associated infertility: ESHRE2022
Endometriosis associated infertility: ESHRE2022
 
Ovulation induction
Ovulation inductionOvulation induction
Ovulation induction
 
Thin Endometrium & Infertility
Thin Endometrium & InfertilityThin Endometrium & Infertility
Thin Endometrium & Infertility
 
PCOS - Ovulation Induction 2 - Dr Bharati Dhorepatil
PCOS - Ovulation Induction 2 - Dr Bharati DhorepatilPCOS - Ovulation Induction 2 - Dr Bharati Dhorepatil
PCOS - Ovulation Induction 2 - Dr Bharati Dhorepatil
 

Similar to Ovarian stimulation oral agents

Oral hormonal contraceptive
Oral hormonal contraceptiveOral hormonal contraceptive
Oral hormonal contraceptivemagdy abdel
 
Hormone therapy in carcinoma breast
Hormone therapy in carcinoma breastHormone therapy in carcinoma breast
Hormone therapy in carcinoma breastSailendra Parida
 
Fertility, Pregnancy, Contraception, Lactation And Endocrine Therapy In Breas...
Fertility, Pregnancy, Contraception, Lactation And Endocrine Therapy In Breas...Fertility, Pregnancy, Contraception, Lactation And Endocrine Therapy In Breas...
Fertility, Pregnancy, Contraception, Lactation And Endocrine Therapy In Breas...Mamdouh Sabry
 
Contraception
ContraceptionContraception
ContraceptionAlya Imad
 
Hormonal therapy in breast cancer
Hormonal therapy in breast cancerHormonal therapy in breast cancer
Hormonal therapy in breast cancerDeepika Malik
 
Contraception, Hormones, Progestogens: Update : Dr. Jyoti agarwal Dr. Sharda ...
Contraception, Hormones, Progestogens: Update : Dr. Jyoti agarwal Dr. Sharda ...Contraception, Hormones, Progestogens: Update : Dr. Jyoti agarwal Dr. Sharda ...
Contraception, Hormones, Progestogens: Update : Dr. Jyoti agarwal Dr. Sharda ...Lifecare Centre
 
Hormone therapy for carcinoma breast
Hormone therapy for carcinoma breastHormone therapy for carcinoma breast
Hormone therapy for carcinoma breastParag Roy
 
Soft & text trial- an overview
Soft & text trial- an overview Soft & text trial- an overview
Soft & text trial- an overview Kundan Singh
 
Contraception-DrElshikh_ (1).ppt
Contraception-DrElshikh_ (1).pptContraception-DrElshikh_ (1).ppt
Contraception-DrElshikh_ (1).pptMohamedsMansaray1
 
Oral contraceptives/ Hormonal contraception
Oral contraceptives/ Hormonal contraceptionOral contraceptives/ Hormonal contraception
Oral contraceptives/ Hormonal contraceptionPranatiChavan
 
Ovarian Stimulation in IUI- Overview. Dr. jyoti Bhaskar, Dr. Sharda Jain, Dr....
Ovarian Stimulation in IUI- Overview. Dr. jyoti Bhaskar, Dr. Sharda Jain, Dr....Ovarian Stimulation in IUI- Overview. Dr. jyoti Bhaskar, Dr. Sharda Jain, Dr....
Ovarian Stimulation in IUI- Overview. Dr. jyoti Bhaskar, Dr. Sharda Jain, Dr....Lifecare Centre
 
Barries, OCPs ,EC,and Injectables.pptx
Barries, OCPs ,EC,and Injectables.pptxBarries, OCPs ,EC,and Injectables.pptx
Barries, OCPs ,EC,and Injectables.pptxGetanehLiknaw
 
Female hormones and contraception
Female hormones and contraceptionFemale hormones and contraception
Female hormones and contraceptionFariha Shikoh
 

Similar to Ovarian stimulation oral agents (20)

Oral hormonal contraceptive
Oral hormonal contraceptiveOral hormonal contraceptive
Oral hormonal contraceptive
 
Hormone therapy in carcinoma breast
Hormone therapy in carcinoma breastHormone therapy in carcinoma breast
Hormone therapy in carcinoma breast
 
Fertility, Pregnancy, Contraception, Lactation And Endocrine Therapy In Breas...
Fertility, Pregnancy, Contraception, Lactation And Endocrine Therapy In Breas...Fertility, Pregnancy, Contraception, Lactation And Endocrine Therapy In Breas...
Fertility, Pregnancy, Contraception, Lactation And Endocrine Therapy In Breas...
 
Contraception
ContraceptionContraception
Contraception
 
Contraception Update April 2019
Contraception Update April 2019Contraception Update April 2019
Contraception Update April 2019
 
Hormonal therapy in breast cancer
Hormonal therapy in breast cancerHormonal therapy in breast cancer
Hormonal therapy in breast cancer
 
Contraception, Hormones, Progestogens: Update : Dr. Jyoti agarwal Dr. Sharda ...
Contraception, Hormones, Progestogens: Update : Dr. Jyoti agarwal Dr. Sharda ...Contraception, Hormones, Progestogens: Update : Dr. Jyoti agarwal Dr. Sharda ...
Contraception, Hormones, Progestogens: Update : Dr. Jyoti agarwal Dr. Sharda ...
 
Hormone therapy for carcinoma breast
Hormone therapy for carcinoma breastHormone therapy for carcinoma breast
Hormone therapy for carcinoma breast
 
Contraception DR.R.MOHAN
Contraception   DR.R.MOHANContraception   DR.R.MOHAN
Contraception DR.R.MOHAN
 
Soft & text trial- an overview
Soft & text trial- an overview Soft & text trial- an overview
Soft & text trial- an overview
 
PCO
PCOPCO
PCO
 
Contraception
ContraceptionContraception
Contraception
 
Contraception
ContraceptionContraception
Contraception
 
Contraception-DrElshikh_ (1).ppt
Contraception-DrElshikh_ (1).pptContraception-DrElshikh_ (1).ppt
Contraception-DrElshikh_ (1).ppt
 
Contraception
ContraceptionContraception
Contraception
 
Oral contraceptives/ Hormonal contraception
Oral contraceptives/ Hormonal contraceptionOral contraceptives/ Hormonal contraception
Oral contraceptives/ Hormonal contraception
 
Family planning
Family planningFamily planning
Family planning
 
Ovarian Stimulation in IUI- Overview. Dr. jyoti Bhaskar, Dr. Sharda Jain, Dr....
Ovarian Stimulation in IUI- Overview. Dr. jyoti Bhaskar, Dr. Sharda Jain, Dr....Ovarian Stimulation in IUI- Overview. Dr. jyoti Bhaskar, Dr. Sharda Jain, Dr....
Ovarian Stimulation in IUI- Overview. Dr. jyoti Bhaskar, Dr. Sharda Jain, Dr....
 
Barries, OCPs ,EC,and Injectables.pptx
Barries, OCPs ,EC,and Injectables.pptxBarries, OCPs ,EC,and Injectables.pptx
Barries, OCPs ,EC,and Injectables.pptx
 
Female hormones and contraception
Female hormones and contraceptionFemale hormones and contraception
Female hormones and contraception
 

More from Ahmad Saber

Role of progestogens in obstetrics and gynecology
Role of progestogens in obstetrics and gynecologyRole of progestogens in obstetrics and gynecology
Role of progestogens in obstetrics and gynecologyAhmad Saber
 
Treatment of Recurrent Pregnancy Loss
Treatment of Recurrent Pregnancy LossTreatment of Recurrent Pregnancy Loss
Treatment of Recurrent Pregnancy LossAhmad Saber
 
Decreased fetal movements 2017
Decreased fetal movements 2017Decreased fetal movements 2017
Decreased fetal movements 2017Ahmad Saber
 
Repeated Implantation failure
Repeated Implantation failureRepeated Implantation failure
Repeated Implantation failureAhmad Saber
 
Decreased fetal movements
Decreased fetal movementsDecreased fetal movements
Decreased fetal movementsAhmad Saber
 
Clomiphene review & cc failure
Clomiphene review & cc failureClomiphene review & cc failure
Clomiphene review & cc failureAhmad Saber
 
Pregnancy of unknown location
Pregnancy of unknown locationPregnancy of unknown location
Pregnancy of unknown locationAhmad Saber
 
Management of endometrial hyperplasia
Management of endometrial hyperplasiaManagement of endometrial hyperplasia
Management of endometrial hyperplasiaAhmad Saber
 

More from Ahmad Saber (8)

Role of progestogens in obstetrics and gynecology
Role of progestogens in obstetrics and gynecologyRole of progestogens in obstetrics and gynecology
Role of progestogens in obstetrics and gynecology
 
Treatment of Recurrent Pregnancy Loss
Treatment of Recurrent Pregnancy LossTreatment of Recurrent Pregnancy Loss
Treatment of Recurrent Pregnancy Loss
 
Decreased fetal movements 2017
Decreased fetal movements 2017Decreased fetal movements 2017
Decreased fetal movements 2017
 
Repeated Implantation failure
Repeated Implantation failureRepeated Implantation failure
Repeated Implantation failure
 
Decreased fetal movements
Decreased fetal movementsDecreased fetal movements
Decreased fetal movements
 
Clomiphene review & cc failure
Clomiphene review & cc failureClomiphene review & cc failure
Clomiphene review & cc failure
 
Pregnancy of unknown location
Pregnancy of unknown locationPregnancy of unknown location
Pregnancy of unknown location
 
Management of endometrial hyperplasia
Management of endometrial hyperplasiaManagement of endometrial hyperplasia
Management of endometrial hyperplasia
 

Ovarian stimulation oral agents

  • 1.
  • 3. Two ideas of ovarian stimulation N.B: The main endogenous hormone modulates endogenous gonadotropins secretion is Estrogen 3‫شعبان‬1436AHMAD SABER
  • 4. As estrogen is the main hormone in regulating production of endogenous gonadotropins SO IT IS A TARGET HORMONE Estrogen Receptor Modulator SERM Clomphine Citerate Tamoxifen Aromatase Enzyme inhibition Letrozole
  • 8. Non-steroidal triphenylethylene derivative Cis / Trans isomerism ( same number of atoms but different orientation Chemical structure & Pharmacokinetics: 3‫شعبان‬1436AHMAD SABER
  • 9. EnclomipheneZuclomiphene More potent antiestrogenic isomerLess potent antiestrogenic action (good?) The main role in ovarian stimulation Minimal role in ovarian stimulation ½ life few daysDetected in the circulation for about one month after last day of administration 62% of clomiphene moleculeOnly 38% of clomiphene molecule Hepatic elimination: avoided in cases of liver impairment Retained in body fat so variable in half life and elimination & dose must be adjusted according to BMI Clomid used Cycle –ON /Cycle-off 3‫شعبان‬1436 Early optimal start may antiestrogenic effect
  • 10. Strong anti estrogen + Weak estrogenic activity Competitive antagonist= 3‫شعبان‬1436AHMAD SABER
  • 11. WhereCCacts? Outside CNS antiestrogenic effect of CC is Hostile 3‫شعبان‬1436AHMAD SABER
  • 13. Due to its site of action, the total daily dose of clomiphene must be taken at one time to optimize entry into the hypothalamic and central nervous system receptor sites 3‫شعبان‬1436AHMAD SABER
  • 14. Hostile actions of CC is due to antagonism of E receptors in the uterus Poor cervical mucus quality or quantity and fewer than five motile sperm was found in 39 of 100 patients referred for gonadotropin ovulation induction and/or IUI because of failure to become pregnant after 3- 8 clomiphene cycles (Dickey 2006). Reduced endometrial thickness See later
  • 15. What antiestrogenic effect forces you to stop CC immediately? 3‫شعبان‬1436AHMAD SABER
  • 17. Initial evaluation & prerequisites before induction TVS scanning Hormonal profile
  • 18. Critical US values for ovulation induction
  • 19. Endometrial changes during ovulation induction • When clomiphene citrate (CC) is used for ovulation induction, endometrial thickness is often decreased compared with spontaneous cycles during and immediately following the days CC is taken, because of its antiestrogen effect • During the late proliferative phase, endometrial thickness increases at a faster rate in CC cycles than in spontaneous cycles as it escapes from the antiestrogen, and the effect of increased estrogen due to multiple follicle growth becomes manifest. 3‫شعبان‬1436AHMAD SABER
  • 20. Double endometrial thickness (mm) in spontaneous (○) and clomiphene citrate (●) cycles (mean + SEM). LH 0 = day of onset of luteinizing hormone surge. *P < 0.05. From Randall and Templeton (1991) [7]. Reproduced with permission of the authors and the publisher, the American Society for Reproductive Medicine (The American Fertility Society). 3‫شعبان‬1436AHMAD SABER
  • 21. How to measure the endometrial thickness Thickness measured in an anterior–posterior view at the widest point from outside to outside in an anterior-posterior view at the widest point (O–O). The pattern is triple-line. 3‫شعبان‬1436
  • 23. 1. Endometrial pattern • A triple-line pattern on the day of hCG administration has been reported by some authors to be necessary for implantation in controlled ovarian hyperstimulation (COH) cycles, where hMG or FSH is administered,. • However, Dickey et al. found no difference in initial pregnancy rate between a triple-line pattern (10.9%) and intermediate pattern (10.2%) in CC and COH cycles for ovulation induction before intrauterine insemination, but noted a difference in continuing pregnancy rates of 9.4% for the triple-line pattern and 7.3% for the intermediate pattern . 3‫شعبان‬1436AHMAD SABER
  • 24. 2. Endometrial thickness Decreased endometrial thickness is linked to failure to conceive and biochemical pregnancy in CC, hMG, and spontaneous cycles[13,14,15]. In a study of endometrial thickness on the day of hCG administration for timed intrauterine insemination (IUI), optimal pregnancy and birth (continuing pregnancy) rates occurred only when endometrial thickness was 9mm or greater on the day of hCG administration (Table 12.1). More importantly, no pregnancies occurred when endometrial thickness was less than 6mm in spontaneous, CC, or hMG IUI cycles [13,14]. 3‫شعبان‬1436AHMAD SABER
  • 25. Endometrial thickness according to ovulation regimen: percent cycles; figures in parentheses are number of cycles Endometrial thickness vs. outcome in ovulation induction intrauterine insemination cycles
  • 26. Ovarian cyst before ovulation induction • Ovarian cysts larger than 4 cm should be assessed by M-B rules according to IOTA trial 2010. • Smaller cysts without cancer characteristics either followed until they resolve or start your induction agent. • COCs has no role in treatment ovarian cyst but may have a role in prevention other cysts formation. 3‫شعبان‬1436AHMAD SABER
  • 27. Dealing with problems detected by US 3‫شعبان‬1436AHMAD SABER Ovarian cyst Thick endometrium
  • 28. Hormonal profile 3‫شعبان‬1436AHMAD SABER Baseline Estradiol CC will be ineffective if E ˂ 45-60 pg/ml ( Disturbed axis) prolactin˃25 mIu/ml Indicates ttt of hyperprolactinemia DHEAS if ˃180 μg/dl indicates adrenal hyperplasia Fasting insulin In cases of insulinresistance associated with PCOs TSH levels 4.5 mIU/mL or higher are diagnostic of subclinicalhypothyroidism.
  • 29. Insulin resistance in PCO cases • Fasting insulin levels greater than 20 lU/mL • Two-hour glucose/insulin response to a 75 g glucose load  Two-hour insulin level of 100–150 lU/mL indicates probable IR, 150–300 lU/mL is diagnostic for IR, and greater than 300 lU/mL indicates severe IR.  Two-hour glucose of 140–199 mg/dL indicates impaired glucose tolerance; 200 mg/dL indicates noninsulin- dependent diabetes (type II diabetes). 3‫شعبان‬1436
  • 30. To summarize, the initial Prerequisites Regular menses TSH Day 21 P Androgen excess DHEAS/17OH P Glucose/Insulin FSH/LH/E Amenorrhea FSH/E PRL hCG Irregular menses TSH FSH/LH/E Glucose/insulin Serum FSH ˂ 25 mIu/ml Endometrial thickness ˂ 6 mm No ovarian cyst ˃ 3 cm serum E levels ˃ menopausal (20 pg/mL)
  • 31. Teratogenic ( Group X) Extended action 8-21 days ( stored in body fat cells, depend on isomer) 3‫شعبان‬1436AHMAD SABER
  • 32. Administration • Starting Day: ☑ 2nd -7th day for 5 days  Not effective if started too early i.e.: serum E ˂45-60 pg/ml  Starting day is affected by length of menstrual cycle ???  Better results of CC induction are obtained with early optimal start as early start result in early disappearance of hostile antiestrogenic effect before luteal phase • Starting Dose: ☑ Depends on BMI (How??) or P level Luteal phase insufficiency needs higher starting dose Follicle 6mm or greater 3‫شعبان‬1436AHMAD SABER
  • 33. 3‫شعبان‬1436AHMAD SABER Relationship of Clomiphene Dose to Weight at Conception
  • 34. Simply, Starting dose in relation to body wt is: 3‫شعبان‬1436AHMAD SABER TamoxifenClomipheneWeight 20 mg25 mg 40 mg50 mg 60 mg100 mg
  • 35. Monitoring of CC induction cycles 3‫شعبان‬1436AHMAD SABER
  • 36. Follicular monitoring 3‫شعبان‬1436 AHMAD SABER Increase in diameter at a rate of 1mm per day until they reach 10 mm, then at a rate of 2mm per day until ovulation (Steinkampf,2008) The highest pregnancy rates occur when there are four follicles 15 mm or larger. When HCG is used to trigger ovulation, highest pregnancy rates are achieved when the lead follicle is 16 mm. All follicles 12 mm or larger (vs. >10mmin gonadotropin cycles) may ovulate and contribute to a multiple pregnancy (Dickey et al., 2001).
  • 37. Endometrial thickness monitoring Preovulatory thickness should be ˃6 mm and better pregnancy rate was found with endometrial thickness 9 mm 3‫شعبان‬1436AHMAD SABER If 5 days post induction…there is thin endometrium: Postpone hCG administration Use Estrogen 4 times/day???? In subsequent cycles use low dose CC or switch to Tamoxifen
  • 38. Postovulatory Progesterone • measured five to seven days after ovulation, to coincide with the day of embryo implantation. • supplementation should be considered in the current cycle and the dose of clomiphene should be increased as 50-mg increments until progesterone levels are 2,000 ng/dL (20 pg/mL) or higher in subsequent cycles. Value: confirmovulation determine if the dose of clomiphene is sufficient.
  • 39. Methods to Increase Pregnancy Rates in Clomiphene Cycles 3‫شعبان‬1436AHMAD SABER 1.Increase number of follicles 2.Improve endometrial and cervical mucous quality 3.IUI